Sentences with phrase «receive chemotherapy treatment»

For instance, to receive chemotherapy treatment for cancer.

Now doctors have investigated the use of crizotinib in patients with ALK positive lung cancer who have not yet received any chemotherapy treatment.

Larsen emphasized that heart failure is by no means inevitable in patients receiving chemotherapy treatment.

Because he is currently in Frankfurt receiving chemotherapy treatment for pancreatic cancer, Tek appeared via video, wearing glasses and a black zip - up pullover, seated before shelves of books, and explained that he has recently been thinking about how his legacy can be «preserved for the benefit of the world.»

Not exact matches

«More than twice the number of patients [were] still living at the end of the study after receiving IMAB362 plus chemotherapy compared to chemotherapy alone,» according to Ganymed CEO Özlem Türeci, with patients showing the highest level of that protein biomarker responding best to the treatment.

If the chemotherapy treatment can not wait until after the pregnancy is completed or if termination of the pregnancy is not an option, a woman can receive chemotherapy during pregnancy.

No polio patient ever received a miracle until the Salk vaccine and I routinely ignored cancer patients until chemotherapy and radiation treatments were developed.

She had been hospitalized a couple of times, received chemotherapy again, and those treatments were followed with the usual discomfort.

Mom is scheduled to get out of the hospital on November 10th — fingers crossed — and has chosen to receive traditional chemotherapy treatment.

After the patient has returned home from the hospital, the next stage of treatment is consolidation, in which patients receive several additional rounds of chemotherapy to build upon the effects of induction.

Pagano, age 51, is expected to spend the next 6 - 8 weeks at the Indiana University Simon Cancer Center receiving and recovering from an initial round of chemotherapy, and then is likely to continue treatment for up to several years to hopefully achieve and maintain remission.

The first - line designation means that some patients will have access to the drug without first having to receive other treatments such as chemotherapy.

The FDA also expanded the approval of pembrolizumab to treat the majority of people with NSCLC who had received prior chemotherapy, greatly increasing the patient population that can benefit from the treatment.

Additionally, due to other medical issues or poor performance status (a measure that considers a patient's quality of life and ability to function during treatment), some stage III NSCLC patients are unable to receive the standard treatment of concurrent chemotherapy and RT..

Once the disease spreads to other parts of the body, most patients are not candidates for surgery and receive chemotherapy as their primary treatment.

In a clinical trial published in June, melanoma patients who received ipilimumab combined with chemotherapy gained a precious extra few months» survival compared with those who received chemo alone, and the treatment nearly doubled the number of patients still living after three years.

Dr. Rassool says that a clinical trial is planned to test whether low doses of a DNMT inhibitor, decitabine, and an investigational PARP inhibitor, talazoparib, can be safely combined and whether this therapy shows efficacy for AML patients, especially those who can not receive intensive chemotherapy, whose leukemia is resistant to treatment, or who have experienced a relapse after treatment.

«The financial burden was higher in patients who received chemotherapy — a potentially lifesaving treatment.

The benefit of chemotherapy, in addition to craniospinal radiation, was seen in adult patients with medulloblastoma (MB), including those with localized disease who received high - dose radiation treatment following surgery.

Many cancer patients that receive chemotherapy go into remission at first, but relapse after treatment is discontinued.

Prior studies that examined the impact of cancer treatment decisions on employment showed that patients who received chemotherapy were most likely to experience longer disruptions in or loss of employment, but changes in breast cancer management in recent years have shifted recommendations away from chemotherapy for early stage breast cancer.

Dr Fiona Blackhall, a senior lecturer in The University of Manchester's Institute of Cancer Sciences and a consultant based at The Christie NHS Foundation Trust — both part of the Manchester Cancer Research Centre — said: «In order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.»

Two patients that had previously not responded to available standard treatments, including surgery, external radiation, hormonal and chemotherapy, have received 225Actinium - PSMA - 617 as experimental therapy.

Chemotherapy treatment usually involves the patient receiving medicine through an intravenous catheter.

This study included 68 childhood cancer survivors who had received cranial irradiation, intrathecal chemotherapy or both for treatment of acute lymphoblastic leukemia (ALL) or brain tumors.

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, «Reactivation of Hepatitis B,» and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

Regardless of disease stage, patients who received surgery lived an average of 57 months, compared to less than 12 months for patients who received only non-surgical treatment (such as chemotherapy or radiation therapy), and 1.4 months for patients who received no treatment at all.

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

Between April 1993 and March 2003, 1011 patients were randomized to four treatment arms, 252 patients received preoperative radiotherapy alone, 253 patients received preoperative radiotherapy — chemotherapy, 253 patients received preoperative radiotherapy followed by adjuvant chemotherapy, and 253 patients received preoperative radiotherapy and chemotherapy followed by adjuvant chemotherapy.

Pauling denied that the study was a replication of Cameron's experiment because the patients used in the Mayo trial had all received chemotherapy before taking vitamin C so their negative response to treatment with vitamin C may have had more to do with their depressed immune system than the inefficacy of vitamin C.

One implication is cancer patients with few mutations in their tumors might respond better to PD - 1 inhibitors if they first receive radiation or chemotherapy, because these treatments can create new mutations in tumors.

All patients who responded received only one prior line of chemotherapy therapy, suggesting that the drug may be an option earlier in the treatment course.

As evidenced by CT scan, the cancer did not grow or spread in all 31 patients who completed chemotherapy, thus all patients received three SABR treatments of 36 Gy each, including a 2 mm expansion around the gross tumor.

The authors report that cognitive function after cancer treatment in memory, processing speeds and executive function was comparable among those women who received chemotherapy with or without anthracycline and those who did not receive chemotherapy.

Patients usually receive surgery, chemotherapy and radiation, but these treatments are not very effective as an estimated 50 percent of GBM patients die within one year, and 90 percent die within three years.

Men with newly diagnosed metastatic, hormone - sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone - blockers, report scientists from Dana - Farber Cancer Institute and the Eastern Co-operative Oncology Group.

This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment — more than a year of additional life.

Typically, all would have received chemotherapy as part of their treatment.

Patients were randomized 1:1 to receive treatment with investigator's choice of chemotherapy or inotuzumab ozogamicin.

The agent was previously approved in December 2016 for the treatment of ovarian cancer specifically associated with BRCA mutations, in women who had received at least two prior chemotherapy regimens.

Among HIV - positive patients with Hodgkin lymphoma, a new study finds that blacks are significantly less likely than whites to receive treatment for the cancer, even though chemotherapy saves lives.

• Documented FGF / FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.

A bid to improve near - zero survival rates for pancreatic cancer will receive a boost with the creation of Australia's first pancreatic cancer «organoids bank», enabling researchers to bring down the time it takes to find individualised chemotherapy treatment within weeks rather than months.

The study, published in November 2016 in The Lancet Oncology and presented with updated outcomes at the October 2017 World Conference on Lung Cancer in Yokohama, Japan, reported that 57 percent of patients receiving the combination therapy responded to treatment, whereas only 31 percent responded to chemotherapy alone.

Before a patient receives a donor's marrow, his or her own marrow must be destroyed by a rigorous treatment of chemotherapy and / or radiation.

Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

Patients receive a personalized, comprehensive approach to care for their benign and malignant brain tumors and are evaluated for multimodality treatments such as chemotherapy, minimally invasive surgical options, and radiation therapy including proton therapy and gamma knife.

In addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).

Women who receive chemotherapy and radiation for breast cancer could be at greater risk for heart disease, even years after treatment, the American Heart Association warned in February 2018.